Oragenics Inc (OGEN)

$1.31 -0.04 (-2.96%)
Market Cap 5.41M
Revenue (ttm) 0.00
Net Income (ttm) -10.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 196,200
Avg Vol 134,812
Day's Range N/A - N/A
Shares Out 4.13M
Stochastic %K 35%
Beta 0.83
Analysts Strong Buy
Price Target $2.00

Company Profile

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002 for the treatment of mild traumatic brain injury, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplif...

Industry: Biotechnology
Sector: Healthcare
Phone: 813 286 7900
Fax: 813 286 7900
Address:
1990 Main Street, Suite 750, Sarasota, United States
RocketQueen
RocketQueen Oct. 4 at 4:01 PM
$OGEN flimsy thought here, but let's say for the sake of argument they are compliant with the NYSE MKt. This compliance does *not help much because as of their last QTR report, they were not compliant and they need to raise more capital beyond the 15M for clinical trials. Also, with cash raises, the price will be pressured below .50. So, a better scenario might be to buy below .40, and then wait to see if Janet gets moving on phase II. Historically, OGEN has lived in the .35-.40 range. Sink or swim there because of the price bid compliance. But this price range is too rich now.
0 · Reply
Spilly0713
Spilly0713 Oct. 4 at 3:16 PM
$OGEN okay, I think that company just doesn’t deal with them anymore. I see a new email on their site. Disregard.
0 · Reply
Spilly0713
Spilly0713 Oct. 4 at 3:10 PM
$OGEN email investor relations and see if you get an automated message saying the email doesn’t exist. I’ve emailed them before and sometimes would get answers. Now the same email apparently doesn’t exist??
0 · Reply
Karimmeshraki
Karimmeshraki Oct. 4 at 1:45 PM
$OGEN I lost 99% of my bag with this scam. Been in red for 5 years.
0 · Reply
markusann
markusann Oct. 3 at 7:42 PM
$OGEN little starter position
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 7:34 PM
$OGEN $AGMH $LYEL $EKSO Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
NMax
NMax Oct. 3 at 5:53 PM
$OGEN why didn't Oragenics notify shareholders that its Chief Medical officer James Kelly would be joining Leigh Steinberg and speaking at the 2nd annual international summit on repetitive brain injury last month Because Janet Huffman appears to be part of an orchestrated attempt at defrauding retail investors? Yet another example Oragenics management manipulating sentiment regarding their asset.
1 · Reply
NMax
NMax Oct. 3 at 1:40 PM
$OGEN continuing to accumulate next week!🤗 Seeya then! 🤑🤑🤑
1 · Reply
MoonCowBoy
MoonCowBoy Oct. 3 at 12:43 AM
$AEMD $INAB $OGEN $AGMH :
0 · Reply
RocketQueen
RocketQueen Oct. 3 at 12:10 AM
$OGEN from the most recent Q report in August. This garbage is going down: "While this subsequent financing mitigates some of the liquidity risk, substantial doubt about our ability to continue as a going concern continues to exist unless and until we obtain additional capital to fund operations beyond the current planning horizon. There can be no assurance that we will be able to obtain such financing on acceptable terms, or at all. If we are unable to raise sufficient capital in the future, we may be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts, which would adversely affect our business prospects and ability to continue as a going concern". Chapter 11 likely around the corner.
3 · Reply
Latest News on OGEN
Oragenics Q2 2025 Shareholder Update

Aug 11, 2025, 8:45 AM EDT - 7 weeks ago

Oragenics Q2 2025 Shareholder Update

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

Jul 16, 2025, 8:39 AM EDT - 2 months ago

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

Oragenics Completes Approximately $16.5 Million Offering

Jul 2, 2025, 4:15 PM EDT - 3 months ago

Oragenics Completes Approximately $16.5 Million Offering

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

Jul 1, 2025, 8:31 AM EDT - 3 months ago

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

May 13, 2025, 8:30 AM EDT - 5 months ago

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

May 12, 2025, 8:30 AM EDT - 5 months ago

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

Apr 7, 2025, 4:30 PM EDT - 6 months ago

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

Mar 27, 2025, 8:30 AM EDT - 6 months ago

Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

Mar 18, 2025, 5:33 PM EDT - 7 months ago

Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

Mar 6, 2025, 9:30 AM EST - 7 months ago

Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment

Feb 25, 2025, 8:30 AM EST - 7 months ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Feb 11, 2025, 8:30 AM EST - 8 months ago

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025

Feb 5, 2025, 8:15 AM EST - 8 months ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025

Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

Jan 21, 2025, 8:15 AM EST - 9 months ago

Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Dec 16, 2024, 8:09 AM EST - 10 months ago

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

Oct 18, 2024, 8:30 AM EDT - 1 year ago

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

Oct 9, 2024, 7:30 AM EDT - 1 year ago

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oct 8, 2024, 8:45 AM EDT - 1 year ago

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oragenics, Inc. Announces Closing of Public Offering

Sep 5, 2024, 4:30 PM EDT - 1 year ago

Oragenics, Inc. Announces Closing of Public Offering

Oragenics, Inc. Announces Pricing of Public Offering

Sep 4, 2024, 8:36 AM EDT - 1 year ago

Oragenics, Inc. Announces Pricing of Public Offering

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Aug 21, 2024, 8:45 AM EDT - 1 year ago

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

Aug 16, 2024, 4:30 PM EDT - 1 year ago

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

Aug 14, 2024, 8:30 AM EDT - 1 year ago

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

Aug 12, 2024, 8:30 AM EDT - 1 year ago

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Aug 8, 2024, 8:45 AM EDT - 1 year ago

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

Jun 27, 2024, 8:30 AM EDT - 1 year ago

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

Oragenics, Inc. Announces Proposed Public Offering

Jun 24, 2024, 6:43 PM EDT - 1 year ago

Oragenics, Inc. Announces Proposed Public Offering

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

May 22, 2024, 8:00 AM EDT - 1 year ago

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

May 17, 2024, 8:00 AM EDT - 1 year ago

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Apr 19, 2024, 5:50 PM EDT - 1 year ago

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Oragenics, Inc. Files 10K and Provides Company Update

Apr 1, 2024, 9:05 AM EDT - 1 year ago

Oragenics, Inc. Files 10K and Provides Company Update

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Mar 18, 2024, 7:00 AM EDT - 1 year ago

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Mar 5, 2024, 7:45 AM EST - 1 year ago

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Oragenics Announces Closing of Public Offering

Mar 1, 2024, 4:04 PM EST - 1 year ago

Oragenics Announces Closing of Public Offering

Oragenics Announces Pricing of Public Offering

Feb 27, 2024, 9:25 PM EST - 1 year ago

Oragenics Announces Pricing of Public Offering

Oragenics Announces Proposed Public Offering

Feb 27, 2024, 4:33 PM EST - 1 year ago

Oragenics Announces Proposed Public Offering

Oragenics, Inc. Announces Leadership Transition

Feb 12, 2024, 4:41 PM EST - 1 year ago

Oragenics, Inc. Announces Leadership Transition

Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement

Feb 7, 2024, 8:00 AM EST - 1 year ago

Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement

Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion

Feb 5, 2024, 8:00 AM EST - 1 year ago

Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion

Oragenics Announces Termination of At-The-Market Offering Program

Jan 23, 2024, 5:34 PM EST - 1 year ago

Oragenics Announces Termination of At-The-Market Offering Program

Oragenics Completes Acquisition of Odyssey Health's Neurological Assets

Jan 2, 2024, 7:30 AM EST - 1 year ago

Oragenics Completes Acquisition of Odyssey Health's Neurological Assets

Oragenics Issues Update to Shareholders

Nov 2, 2023, 7:00 AM EDT - 2 years ago

Oragenics Issues Update to Shareholders

Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc.

Oct 18, 2023, 8:30 AM EDT - 2 years ago

Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc.

Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors

Oct 18, 2023, 8:30 AM EDT - 2 years ago

Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors

Oragenics to Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate

Oct 5, 2023, 6:30 AM EDT - 2 years ago

Oragenics to Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate

Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets

Sep 29, 2023, 4:00 PM EDT - 2 years ago

Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets

Oragenics, Inc. Announces Private Placement

Aug 7, 2023, 8:30 AM EDT - 2 years ago

Oragenics, Inc. Announces Private Placement

Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM

Jun 5, 2023, 4:18 PM EDT - 2 years ago

Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM

Oragenics to Participate in the World Vaccine Congress Washington

Mar 29, 2023, 11:45 AM EDT - 2 years ago

Oragenics to Participate in the World Vaccine Congress Washington

Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE

Mar 14, 2023, 8:30 AM EDT - 2 years ago

Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE

RocketQueen
RocketQueen Oct. 4 at 4:01 PM
$OGEN flimsy thought here, but let's say for the sake of argument they are compliant with the NYSE MKt. This compliance does *not help much because as of their last QTR report, they were not compliant and they need to raise more capital beyond the 15M for clinical trials. Also, with cash raises, the price will be pressured below .50. So, a better scenario might be to buy below .40, and then wait to see if Janet gets moving on phase II. Historically, OGEN has lived in the .35-.40 range. Sink or swim there because of the price bid compliance. But this price range is too rich now.
0 · Reply
Spilly0713
Spilly0713 Oct. 4 at 3:16 PM
$OGEN okay, I think that company just doesn’t deal with them anymore. I see a new email on their site. Disregard.
0 · Reply
Spilly0713
Spilly0713 Oct. 4 at 3:10 PM
$OGEN email investor relations and see if you get an automated message saying the email doesn’t exist. I’ve emailed them before and sometimes would get answers. Now the same email apparently doesn’t exist??
0 · Reply
Karimmeshraki
Karimmeshraki Oct. 4 at 1:45 PM
$OGEN I lost 99% of my bag with this scam. Been in red for 5 years.
0 · Reply
markusann
markusann Oct. 3 at 7:42 PM
$OGEN little starter position
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 7:34 PM
$OGEN $AGMH $LYEL $EKSO Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
NMax
NMax Oct. 3 at 5:53 PM
$OGEN why didn't Oragenics notify shareholders that its Chief Medical officer James Kelly would be joining Leigh Steinberg and speaking at the 2nd annual international summit on repetitive brain injury last month Because Janet Huffman appears to be part of an orchestrated attempt at defrauding retail investors? Yet another example Oragenics management manipulating sentiment regarding their asset.
1 · Reply
NMax
NMax Oct. 3 at 1:40 PM
$OGEN continuing to accumulate next week!🤗 Seeya then! 🤑🤑🤑
1 · Reply
MoonCowBoy
MoonCowBoy Oct. 3 at 12:43 AM
$AEMD $INAB $OGEN $AGMH :
0 · Reply
RocketQueen
RocketQueen Oct. 3 at 12:10 AM
$OGEN from the most recent Q report in August. This garbage is going down: "While this subsequent financing mitigates some of the liquidity risk, substantial doubt about our ability to continue as a going concern continues to exist unless and until we obtain additional capital to fund operations beyond the current planning horizon. There can be no assurance that we will be able to obtain such financing on acceptable terms, or at all. If we are unable to raise sufficient capital in the future, we may be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts, which would adversely affect our business prospects and ability to continue as a going concern". Chapter 11 likely around the corner.
3 · Reply
1Spartantrade1
1Spartantrade1 Oct. 2 at 6:38 PM
Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $AEMD $INAB $OGEN $AGMH 🚀
0 · Reply
NMax
NMax Oct. 2 at 5:33 PM
$OGEN 1000% manipulated but someone still wants this to go up
0 · Reply
XAMN
XAMN Oct. 2 at 3:47 PM
$OGEN #Jailtime-for-Janet is trending
1 · Reply
DJT24
DJT24 Oct. 2 at 2:09 PM
$OGEN ODYY has been on fire. Surprised this isn’t moving.
0 · Reply
NMax
NMax Oct. 2 at 12:46 PM
$OGEN Fake compliance deadline orchestrated by Oragenics and their market maker I'll be adding while they continue to spin this BS Thank you! 🤑🤑🤑
0 · Reply
Spilly0713
Spilly0713 Oct. 2 at 11:11 AM
$OGEN bullish or bearish, we should get some major news on the compliance update. No one knows what they’ll decide or what OGEN will do. Regardless, this is big for either side
1 · Reply
botanist
botanist Oct. 2 at 1:47 AM
$OGEN my average here is $483. Sell on pops
0 · Reply
NMax
NMax Oct. 2 at 12:45 AM
$OGEN A known shorter telling people to stay away...hmmm I think I'll add 🤑🤑🤑
0 · Reply
mi_ama_llama
mi_ama_llama Oct. 2 at 12:44 AM
$OGEN how do you dumba$$ES keep doing this. You think because it has one good day is gotta give it all up. Just over 5k AH and this is the best you can do...keep shorting so it can go up! Janet Puffman and Co gonna be buying the dip before the rip...
0 · Reply
RocketQueen
RocketQueen Oct. 1 at 11:09 PM
$OGEN biotech stocks are too risky to hold, and you could lose a lot. I just noticed $KALA failed in their clinical trials and literally dropped from over 20.00 USD to now trading near the same price as scam OGEN under 1.50 USD. If you like risk, you'd be better off with KALA as this is way underpriced unless they file chapter 11. Moral: stay out of pennies.
2 · Reply
Makethatmoneyson
Makethatmoneyson Oct. 1 at 10:18 PM
$OGEN
0 · Reply
NMax
NMax Oct. 1 at 9:51 PM
$OGEN Y'all aren't fooling anyone on this board at this point, but let's keep going. The average is loving it. 😁
0 · Reply